摘要
目的 观察格列美脲降糖效果和安全性 ,并与达美康比较。方法 选用 86例Ⅱ型糖尿病患者 ,其中治疗组 3 9例 ,给予格列美脲片 1～ 4mg ,每日 1次。对照组 47例 ,给予达美康片 40～ 160mg ,每日 2次。每周观察两组空腹血糖 (FPG) ,餐后2h血糖 (2HPG) ,糖化血红蛋白 (HbA1C) ,体质指数 (BMl) ,低血糖事件等 ,并进行临床疗效评定。结果 治疗组与对照组 ,FPG与 2HPG在服用 1周后即有所下降 ,服用 12周 ,FPG分别下降 2 .60和 2 .79mmol/L ;2HPG分别下降 5 .45和 5 .19mmol/L ;HbAlC也有不同程度下降 ,较基础值有统计学意义。MBI均变化不大 ,无统计学意义。结论 格列美脲与达美康两组对控制FPG、2HPG及HbAlC有显效 ,疗效相似。对体重影响相似 ;两组均有低血糖事件发生 ,但治疗组少于对照组。
To observe the effect and safety of Glimepiride in reducing blood sugar and compare it with Diamicron. 86 cases of type II diabetes were selected, 39 cases of the case group were administrated with GMD (1～4 mg, qd. po); 47 cases of the control group were administrated with Diamicron (40～160 mg, Bid, po). FPG, 2 HPG, HbA 1C,BMI and hypoglycemia of both the two groups were observed, and the clinical effect was evaluated. Both the case group and the control group were found with a decrease of FPG and 2 HPG after administration for 1 week; after administration for 12 weeks, FPG decreased by 2.60 mmol/L in the case group and 2.79 mmol/L in the control group; 2 HPG decreased by 5.45 mmol/L in the case group and 5.19 mmol/L in the control group; HbA 1C also decreased to some extent in both the two groups. The result has statistic significance compared with the standard value. MBI showed no obvious changes, it has no statistic significance. [Conclusion] Both Glimepiride and Diamicron have significant effect in controlling FPG, 2HPG and HbA 1C, the curative effect of them is similar. Both the two groups have hypoglycemia, but it appeared less in the case group.
出处
《职业与健康》
CAS
2004年第10期157-158,共2页
Occupation and Health
